The Cigna Group CI
AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more
Business Model#
What the company does and how it earns its money; written AI-editorially, exclusively from the company's original reports, without any assessment of our own.
The Cigna Group is a global health services organization that operates through two principal segments. Evernorth Health Services delivers pharmacy benefit management through its Pharmacy Benefit Services unit and specialty pharmacy and care delivery through its Specialty and Care Services unit, serving employers, health plans, and government clients. Cigna Healthcare provides employer-sponsored medical, dental, behavioral health, and pharmacy benefits to U.S. commercial customers across National Accounts, Middle Market, and Select employer segments. Revenue is generated through insurance premiums, pharmacy revenues, and fees from benefit administration and service arrangements. Following the 2025 divestiture of Medicare Advantage and related government health businesses to HCSC, and with the announced January 2027 exit from Individual and Family Plans, the company is concentrating its health benefits franchise on commercial employer coverage while expanding pharmacy benefit management and care services through Evernorth.
Current Status#
Summary of the most recent reporting period: core figures, drivers and management statements; written editorially from the current original report, every figure backed by a source number.
Price & Chart#
Interactive price chart (TradingView) and the trend of key figures from the core tables. The price chart loads only after a click; at that point a connection to TradingView is established.
Daily candles with news and earnings markers. Loads only on click.
Share-Price Drivers#
Factors the company itself names as material for its business development (IR-based); reproduced neutrally, no price forecast and no assessment of our own.
Evernorth is the dominant revenue engine, with Pharmacy Benefit Services at $33.0bn (+11%) and Specialty and Care Services at $25.4bn (+6%) in the latest quarter, while total revenue rose to $71.7bn in 2026-Q2 with guidance raised 28 29
Segment revenue $33.0bn, +11% growth; supported by the multi-year Centene pharmacy benefit management agreement effective 2024 28 18
Segment revenue $25.4bn, +6% growth, extended by the Shields Health Solutions investment and DoD TRICARE Specialty Pharmacy expansion 28 26 10
New model repeatedly signalled since 2025 with a 2027 launch plan; traction not yet reflected in reported revenue 26 27 24
Launched 2025 to serve GLP-1 demand within Evernorth's specialty offering 26
Sale of Medicare Advantage and related businesses to HCSC completed Q1 2025 and planned exit from Individual and Family Plans medical business effective 2027 remove lower-margin insurance revenue 23 29 30
Accelerated Share Repurchase agreements and dividend increase reduced diluted shares from ~273m (2025-Q1) toward ~264m (2026-Q2) 13 9
Sector trend: Managed-care KPIs point to top-line demand still accelerating, led by pharmacy and specialty services volumes, while the group prunes lower-margin insurance lines (Medicare, Individual and Family Plans) to lift profitability 28 29 23
Event Timeline#
This timeline collects the material events from the original reports: guidance changes, revenue and margin signals, strategy shifts, product and M&A announcements. Events are grouped by quarter (most recent first); the grey tag before each event names the event type, the date is the publication date of the source. Management quotes open the quarter block as direct quotes. Per quarter we show the three most defining events; more can be expanded per quarter, older years are collapsed. Every event carries its source as a superscript, clickable number.
2026 · 6 events
2026-Q2 · Apr – Jun 2026
Shareholders' net income increased 8% to $1,660 million ($6.29 per share vs. $5.71 in Q2 2025), with adjusted income from operations up 6% to $2.1 billion 30
2026 outlook for adjusted income from operations per share raised to at least $30.45, following prior Q1 raise to $30.35 30
In April 2026, company announced planned exit from Individual and Family Plans medical business as of January 1, 2027 30
2026-Q1 · Jan – Mar 2026
Shareholders' net income increased 25% to $1,654 million ($6.26 per share vs. $4.85 in Q1 2025), primarily reflecting higher adjusted income from operations in Cigna Healthcare and Evernorth Health Services 27
Medical care ratio decreased 240 basis points to 79.8%, primarily due to base effect of HCSC transaction (divestiture of Medicare Advantage and related businesses completed March 19, 2025) 27
2026 outlook for adjusted income from operations per share raised to at least $30.35, up $0.10 from prior projection 28
2025 · 15 events
2025-Q4 · Oct – Dec 2025
Full-year adjusted income from operations increased 4% to $8.0 billion ($29.84 per share) from $7.7 billion ($27.33 per share) in 2024 25
Cigna Healthcare full-year MCR was 84.4% compared to 83.2% in 2024, primarily due to higher medical costs driven by the Individual and Family Plans business 25
2026 outlook established with adjusted income from operations of at least $7.950 billion, or at least $30.25 per share 25
2025-Q3 · Jul – Sep 2025
Total revenues increased 10% to $69.7 billion, primarily driven by Evernorth Health Services growth 24
Cigna Healthcare MCR increased to 84.8% from 82.8% in Q3 2024, driven by Individual and Family Plans business and higher stop loss medical costs 24
Evernorth Health Services announced transformational rebate-free pharmacy benefit model designed to lower drug costs, improve transparency, and support local pharmacies 24
Operating cash flow reached 3,418.0 USDm vs 46.0 USDm in 2024-Q3 (×74.3). 23
2025-Q2 · Apr – Jun 2025
Total revenues increased 11% to $67.2 billion, primarily driven by Evernorth Health Services including growth of existing client relationships and strong specialty pharmacy growth 22
Cigna Healthcare MCR was 83.2% for Q2 2025 compared to 82.3% for Q2 2024, primarily due to expected higher stop loss medical costs 22
2025 outlook for adjusted income from operations of at least $29.60 per share reaffirmed 22
2025-Q1 · Jan – Mar 2025
Cigna Healthcare MCR rose to 82.2% from 79.9% in Q1 2024, primarily driven by expected higher stop loss medical costs 20
2025 adjusted income from operations guidance raised to at least $29.60 per share 20
Divestiture of Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses to HCSC completed for $4.8 billion purchase price 19
2024 · 13 events
2024-Q4 · Oct – Dec 2024
Q4 adjusted income from operations decreased 8% from Q4 2023, primarily driven by lower Cigna Healthcare contributions due to higher stop loss medical costs 17
Full year 2024 revenues +27% to $247.1B; total customer relationships increased 11% to 182.2 million and pharmacy customers grew 22% to 120.0 million driven by Evernorth Health Services expansion 17
Full year Cigna Healthcare MCR increased to 83.2% from 81.3% in 2023, primarily driven by higher stop loss medical costs, contributing to a 6% full-year decline in Cigna Healthcare adjusted income from operations 17
Operating cash flow reached 5,212.0 USDm vs 1,467.0 USDm in 2023-Q4 (×3.6). 125
2024-Q3 · Jul – Sep 2024
Q3 adjusted income from operations $7.51/share vs $6.77/share in Q3 2023, with Evernorth Health Services up 9% and Specialty and Care Services up 23%; Cigna Healthcare down 4% driven by higher MCR 16
Q3 shareholders' net income $2.63/share, reduced by a $1.0B non-cash after-tax investment loss from a second impairment of VillageMD equity securities 16
Q3 revenues +30% to $63.7B, driven by Evernorth Health Services large client wins, specialty volume growth, and increased Humira biosimilar adoption 16
2024-Q2 · Apr – Jun 2024
Q2 adjusted income from operations $6.72/share vs $6.13/share in Q2 2023, reflecting Evernorth Health Services growth of 30% in adjusted revenues and 7% in adjusted income 14
Q2 revenues +25% to $60.5B, driven by Evernorth Health Services Pharmacy Benefit Services reflecting large client wins including Centene and organic growth; Pharmacy Benefit Services adjusted revenues +41% 14
Cigna Healthcare MCR 82.3% in Q2, including approximately 40 bps of unfavorable prior-year Medicare Advantage risk adjustment revenue impacts 14
2024-Q1 · Jan – Mar 2024
Shareholders' net loss of $0.97/share in Q1, including a $1.8B non-cash after-tax investment loss from impairment of VillageMD equity securities 12
Q1 revenues +23% YoY, driven by Centene Corporation onboarding at the start of 2024, which increased pharmacy revenues 31% within Evernorth Health Services 11
Definitive agreement signed to sell Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses to Health Care Service Corporation for approximately $3.7 billion, expected to close Q1 2025 11
2023 · 13 events
2023-Q4 · Oct – Dec 2023
Entered definitive agreement to sell Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses to Health Care Service Corporation for $3.3 billion cash, subject to regulatory approvals (10)
Full-year 2023 revenues reached $195.3 billion, up from $180.5 billion in 2022; adjusted income from operations $7.4 billion ($25.09 per share) vs. $7.3 billion ($23.36 per share) in prior year (9)
2024 adjusted income from operations guidance initiated at at least $8.025 billion, or at least $28.25 per share (9)
2023-Q3 · Jul – Sep 2023
Adjusted income from operations increased 8% to $2.0 billion ($6.77 per share), reversing the year-over-year declines in Q1 and Q2 that had reflected the absence of businesses divested in the 2022 Chubb transaction (8)
Total revenues increased 8% to $49.0 billion; Evernorth Health Services adjusted revenues up 8% and Cigna Healthcare adjusted revenues up 14%, with premiums up 15% reflecting insured customer growth (8)
2023 adjusted EPS outlook raised to at least $24.75 per share from prior projection of at least $24.70 (8)
2023-Q2 · Apr – Jun 2023
Total revenues increased 7% to $48.6 billion; Evernorth Health Services adjusted revenues up 10% and Cigna Healthcare adjusted revenues up 12%, driven by specialty growth and customer expansion (6)
2023 full-year adjusted revenue guidance raised to at least $190.0 billion; operating cash flow guidance raised to at least $9.5 billion (6)
Evernorth Health became minority owner in CarepathRx Health Systems Solutions through a $437 million equity method investment in July 2023 to provide integrated hospital pharmacy solutions (5)
2023-Q1 · Jan – Mar 2023
Total revenues increased 6% to $46.5 billion; Evernorth adjusted revenues up 8% and Cigna Healthcare adjusted revenues up 12%, reflecting specialty pharmacy growth and insured customer expansion (4)
Cigna Healthcare medical care ratio decreased 20 basis points to 81.3%, reflecting effective pricing execution and favorable cost trends including lower COVID-19 costs (3)
2023 adjusted income from operations outlook raised to at least $24.70 per share (4)
Operating cash flow reached 5,028.0 USDm vs 2,030.0 USDm in 2022-Q1 (×2.5). 3
Key Figures ($m)#
The company's core financial figures in three views, one below the other: fiscal years (as reported; after restatements the table shows the most recent filing version, marked), half-years (6-month basis, H2 = second half on its own) and quarters (3-month basis, not cumulative). Each row is one period, most recent first. Values with a dotted underline are clickable and show the raw value, the exact source location, the scale evidence and the source; derived values additionally show their formula and inputs. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original.
All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.
Fiscal years
| Period | Revenue | Op. income | Op. income (adj.) | Net income | EPS ($) | OCF | Source |
|---|---|---|---|---|---|---|---|
| FY2025 | 274,900 | 9,200 | -387.89 | 5,957 | 22.18 | 9,601 | 26 |
| FY2024 | 247,121 | 9,417 | 7,741 | 3,434 | 12.12 | 10,363 | 18 |
| FY2023 | 195,265 | 8,536 | 7,448 | 5,164 | 17.39 | 11,813 | 10 |
Quarters
| Period | Published | Revenue | Op. income | Op. income (adj.) | Net income | EPS ($) | Cash | Net Debt | Net Debt/EBITDA (x) | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-Q2* | 2026-07-30 | 71,668 | 2,676 | 7.78 | 1,660 | 6.29 | 6,298 | 25,580 | 2x (LTM) | 29 |
| 2026-Q1* | 2026-04-30 | 68,494 | 2,358 | 2,058 | 1,654 | 6.26 | 7,040 | 23,860 | 1.9x (LTM) | 27 |
| 2025-Q4* | 2026-02-05 | 72,472 | 2,345 | 8.08 | 1,234 | 4.59* | 7,676 | 23,787 | 2x (LTM) | 25 |
| 2025-Q3* | 2025-10-30 | 69,748 | 2,578 | 7.83 | 1,868 | 6.98 | 6,025 | 28,015 | 2.4x (LTM) | 23 |
| 2025-Q2* | 2025-07-31 | 67,178 | 2,306 | 7.2 | 1,532 | 5.71 | 4,329 | 26,439 | 2.3x (LTM) | 21 |
| 2025-Q1* | 2025-05-02 | 65,502 | 1,971 | -411 | 1,323 | 4.85 | 8,334 | 22,114 | 1.9x (LTM) | 19 |
| 2024-Q4* | 2025-01-30 | 65,649 | 2,173 | 1,845 | 1,424 | 5.03* | 7,550 | 24,422 | 2x (LTM) | 17 |
| 2024-Q3* | 2024-10-31 | 63,694 | 2,576 | 2,112 | 739 | 2.63 | 5,888 | 26,914 | 2.2x (LTM) | 15 |
| 2024-Q2* | 2024-08-01 | 60,523 | 2,412 | 1,909 | 1,548 | 5.45 | 6,788 | 25,104 | 2.1x (LTM) | 13 |
| 2024-Q1* | 2024-05-02 | 57,255 | 2,256 | 6.47 | -277 | -0.97 | 8,439 | 24,329 | 2.1x (LTM) | 11 |
| 2023-Q4* | 2024-02-29 | 51,114 | 2,060 | 7,429.7 | 1,029 | 3.47* | 7,822 | 23,108 | 2x (LTM) | 10 |
| 2023-Q3* | 2023-11-02 | 49,048 | 2,240 | 2,000 | 1,408 | 4.74 | 8,497 | 22,643 | 2x (LTM) | 7 |
| 2023-Q2* | 2023-08-03 | 48,586 | 2,221 | 1,820 | 1,460 | 4.92 | 9,585 | 23,148 | 2.1x (LTM) | 5 |
| 2023-Q1* | 2023-05-05 | 46,517 | 2,015 | 1,115 | 1,267 | 4.24 | 7,935 | 24,607 | 2.2x (LTM) | 3 |
Balance Sheet & Cash Flow ($m)#
Point-in-time balance sheet items (e.g. cash, financial debt) and cash flow items (operating cash flow, investments/capex) per fiscal year, half-year and quarter. Balance sheet values are as of the period end, flow items cover the period. Derived values are marked and are calculated, for example, as: net debt = financial debt − cash; free cash flow = operating cash flow − capex; the click popover shows formula and inputs. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original.
Fiscal years
| Period | Published | Cash | Debt | Net Debt | D&A | OCF | Source |
|---|---|---|---|---|---|---|---|
| FY2025 | 2026-02-26 | 7,676 | 31,463 | 23,787 | 2,775 | 9,601 | 26 |
| FY2024 | 2025-01-30 | 7,550 | 31,972 | 24,422 | 2,775 | 10,363 | 17 |
| FY2023 | 2024-02-29 | 7,822 | 30,930 | 23,108 | 3,035 | 11,813 | 10 |
Quarters
| Period | Published | Cash | Debt | Net Debt | D&A | OCF | Source |
|---|---|---|---|---|---|---|---|
| 2026-Q2 | 2026-07-30 | 6,298 | 31,878 | 25,580 | 655 | -421 | 29 |
| 2026-Q1 | 2026-04-30 | 7,040 | 30,900 | 23,860 | 650 | 1,131 | 27 |
| 2025-Q4 | 2026-02-05 | 7,676 | 31,463 | 23,787 | 722 | 6,149 | 25 |
| 2025-Q3 | 2025-10-30 | 6,025 | 34,040 | 28,015 | 697 | 3,418 | 23 |
| 2025-Q2 | 2025-07-31 | 4,329 | 30,768 | 26,439 | 682 | -1,886 | 21 |
| 2025-Q1 | 2025-05-02 | 8,334 | 30,448 | 22,114 | 674 | 1,920 | 19 |
| 2024-Q4 | 2025-01-30 | 7,550 | 31,972 | 24,422 | 646 | 5,212 | 17 |
| 2024-Q3 | 2024-10-31 | 5,888 | 32,802 | 26,914 | 650 | 46 | 15 |
| 2024-Q2 | 2024-08-01 | 6,788 | 31,892 | 25,104 | 738 | 265 | 13 |
| 2024-Q1 | 2024-05-02 | 8,439 | 32,768 | 24,329 | 741 | 4,840 | 11 |
| 2023-Q4 | 2024-02-29 | 7,822 | 30,930 | 23,108 | 765 | 1,467 | 10 |
| 2023-Q3 | 2023-11-02 | 8,497 | 31,140 | 22,643 | 766 | 2,826 | 7 |
| 2023-Q2 | 2023-08-03 | 9,585 | 32,733 | 23,148 | 755 | 2,492 | 5 |
| 2023-Q1 | 2023-05-05 | 7,935 | 32,542 | 24,607 | 749 | 5,028 | 3 |
Revenue by Type (as of 2026-Q2 · USDm · 4/6)#
Revenue split by segment or product type, exactly as the company itself reports it. The basis is stated next to each value (3, 6 or 12 months); segment totals can deviate from group revenue (reconciliation/consolidation items). If the company changes its segment structure, older structures are kept in the expandable part. Rows in grey are no longer reported separately by the company; they show the last available figures and are never extrapolated.
| Segment | Since | Period | Basis | Revenue | Growth | Margin | Source |
|---|---|---|---|---|---|---|---|
| Other Operations | 2023-Q1 | 2026-Q2 | 3M | 131 | -29% | 16% | 29 |
| Pharmacy Benefit Services | 2024-Q1 | 2026-Q1 | 3M | 33,002 | 11% | – | 28 |
| Specialty and Care Services | 2024-Q1 | 2026-Q1 | 3M | 25,440 | 6% | – | 28 |
| Evernorth Health Services | 2022-Q2 | 2026-Q1 | 3M | 58,442 | 9% | 2.5% | 28 |
| Evernorth Health Services - Pharmacy Benefit Services | 2024-Q2 | FY2024 | 3M | 111,822 | 46% | – | 18 |
| Evernorth Health Services - Specialty and Care Services | 2024-Q2 | FY2024 | 3M | 90,333 | 18% | – | 18 |
Products & M&A (4/7 active+recent)#
Product announcements from the reports; market launches, approvals, partnerships; with first mention (date) and source. “Active/current” means: still mentioned in the most recent reports; what the company no longer mentions moves to the expandable part but is never deleted. Rows in grey are discontinued products.
| Product/Line | Since | Status | Source |
|---|---|---|---|
| Rebate-free model business plan | 2026-03 | Launched | 27 |
| Rebate-free pharmacy benefit model (2x) | 2025-09 | Launched | 26 |
| Strategic Optimization Program | 2025-03 | Launched | 26 |
| EnGuide Pharmacy for GLP-1 medications | 2025 | Launched | 26 |
| DoD TRICARE Specialty Pharmacy expansion | 2024 | Launched | 10 |
| The Cigna Group Ventures strategic venture fund (2x) | 2023 | Launched | 18 |
| Pathwell Bone & Joint product launch | 2023 | Launched | 10 |
M&A (20)#
All recorded acquisitions (purchases) and divestitures/exits with date, short description and source; deliberately including smaller transactions that summaries often miss. Purchase prices appear only where the company itself has disclosed them. Rows in grey are cancelled transactions; the cancellation date is shown in the row.
Acquisitions
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| Shields Health Solutions investment | 2025-08 | Completed | 26 |
| Dividend Increase | 2024-02 | Completed | 9 |
| Centene Corporation Onboarding | 2024-01 | Completed | 11 |
| Organizational Efficiency Plan | 2024 | Completed | 9 |
| Express Scripts and Prime Therapeutics LLC agreement for pharmacy network and specialty pharmacy services | 2024 | Announced | 18 |
| Centene multi-year pharmacy benefit agreement (3×) | 2024 | Announced | 18 |
| Accelerated Share Repurchase Agreements (2×) | 2024 | Announced | 13 |
| Senior notes repayment | 2023-07 | Completed | 5 |
| 5.685% senior notes issuance (3×) | 2023-03 | Completed | 13 |
| VillageMD investment (6×) | 2023 | Completed | 18 |
| Share repurchase program | 2023 | Completed | 8 |
| CarepathRx Health Systems Solutions minority ownership investment (2×) | 2023 | Completed | 5 |
Divestitures / exits
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| Exit from Individual and Family Plans medical business (2×) | 2027-01 | Divested | 29 |
| HCSC transaction | 2025-03 | Divested | 26 |
| HCSC transaction - Sale of Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, and CareAllies businesses (13×) | 2024-01 | Divested | 10 |
| Sale of Medicare businesses to HCSC (7×) | 2024 | Divested | 23 |
| New York Life supplemental behavioral coverage contract non-renewal | 2023 | Divested | 8 |
| Chubb transaction - sale of life, accident and supplemental health benefits business | 2022-07 | Divested | 7 |
| Joint venture in Türkiye divestiture | 2022 | Divested | 10 |
| Chubb international life insurance and supplemental benefits sale | 2022 | Divested | 10 |
Reported KPIs (as disclosed) (360)#
Figures the company discloses itself in addition to the standard financials; order intake, recurring revenue, user or unit counts, adjusted measures. These “story KPIs” usually slip through standard databases; here they are collected as reported, with no calculation of our own. Important: the definition comes from the company itself and can differ from firm to firm; period and source are stated next to every value.
| Date | Period | KPI | Value / change | Source |
|---|---|---|---|---|
| 2026-07-30 | 2026-Q2 | Unpaid claims and claim expenses | 5,228 (USD millions) | 29 |
| 2026-07-30 | 2026-Q2 | Undrawn committed capacity under revolving credit agreement | 6.5 | 29 |
| 2026-07-30 | 2026-Q2 | Total revenues | 71,668 (USD millions) | 29 |
| 2026-07-30 | 2026-Q2 | Total medical customers | 18,413 | 29 |
| 2026-07-30 | 2026-Q2 | Total Pharmacy Customers | 118,243 | 30 |
| 2026-07-30 | 2026-Q2 | Total Medical Customers | 18,413 | 30 |
| 2026-07-30 | 2026-Q2 | Total Customer Relationships | 182,765 | 30 |
| 2026-07-30 | 2026-Q2 | Share repurchases | 250 | 29 |
| 2026-07-30 | 2026-Q2 | Premiums | 9,859 | 29 |
| 2026-07-30 | 2026-Q2 | Pharmacy revenues | 57,172 (USD millions) | 29 |
| 2026-07-30 | 2026-Q2 | Other long-term investments | 5.2 (USD billions) | 29 |
| 2026-07-30 | 2026-Q2 | Net investment income | 272 (USD millions) | 29 |
| 2026-07-30 | 2026-Q2 | Medical care ratio | 84.5% | 29 |
| 2026-07-30 | 2026-Q2 | Fees and other revenues | 4,365 (USD millions) | 29 |
| 2026-07-30 | 2026-Q2 | Dental Customers | 18,488 | 30 |
| 2026-07-30 | 2026-Q2 | Debt-to-capitalization ratio | 42.8% | 29 |
| 2026-07-30 | 2026-Q2 | Debt securities portfolio carrying value | 8.5 (USD billions) | 29 |
| 2026-07-30 | 2026-Q2 | Commercial paper program outstanding balance | 1.0 | 29 |
| 2026-07-30 | 2026-Q2 | Commercial mortgage loan portfolio | 1.2 (USD billions) | 29 |
| 2026-07-30 | 2026-Q2 | Cigna Healthcare Medical Care Ratio | 84.5% | 30 |
| 2026-07-30 | 2026-Q2 | Cash and short-term investments | 6.6 (USD billions) | 29 |
| 2026-07-30 | 2026-Q2 | Capital expenditures | 0.6 (USD billions) | 29 |
| 2026-07-30 | 2026-Q2 | Behavioral Care Customers | 27,621 | 30 |
| 2026-04-30 | 2026-Q1 | Unpaid claims and claim expenses | $4,920 | 27 |
| 2026-04-30 | 2026-Q1 | Undrawn committed capacity revolving credit | $6.5 billion | 27 |
| 2026-04-30 | 2026-Q1 | Other long-term investments | $5.2 billion | 27 |
| 2026-04-30 | 2026-Q1 | Medical customers total | 18,334 | 27 |
| 2026-04-30 | 2026-Q1 | Debt to capitalization ratio | 42.3% | 27 |
| 2026-04-30 | 2026-Q1 | Commercial mortgage loan portfolio | $1.3 billion | 27 |
| 2026-04-30 | 2026-Q1 | Cash and short-term investments | $7.3 billion | 27 |
| 2026-04-30 | 2026-Q1 | Total Pharmacy Customers | 121,020 | 28 |
| 2026-04-30 | 2026-Q1 | Total Medical Customers | 18,334 | 28 |
| 2026-04-30 | 2026-Q1 | Total Customer Relationships | 185,470 | 28 |
| 2026-04-30 | 2026-Q1 | Specialty and Care Services Adjusted Revenues | 25,440 (USD millions) | 28 |
| 2026-04-30 | 2026-Q1 | Shareholders' Equity Per Share | 159.59 | 28 |
| 2026-04-30 | 2026-Q1 | Shareholders' Equity | 42,210 | 28 |
| 2026-04-30 | 2026-Q1 | SG&A Expense Ratio | 5.4% | 28 |
| 2026-04-30 | 2026-Q1 | Pharmacy Benefit Services Adjusted Revenues | 33,002 (USD millions) | 28 |
| 2026-04-30 | 2026-Q1 | Evernorth Health Services Adjusted Revenues | 58,442 (USD millions) | 28 |
| 2026-04-30 | 2026-Q1 | Debt-to-Capitalization Ratio | 42.3% | 28 |
| 2026-04-30 | 2026-Q1 | Cigna Healthcare Medical Care Ratio | 79.8% | 28 |
| 2026-04-30 | 2026-Q1 | Cigna Healthcare Adjusted Revenues | 11,477 (USD millions) | 28 |
| 2026-04-30 | 2026-Q1 | Adjusted SG&A Expense Ratio | 4.8% | 28 |
| 2026-02-26 | FY2025 | Voluntary Turnover Rate | 9% | 26 |
| 2026-02-26 | FY2025 | US Patents | over 540 | 26 |
| 2026-02-26 | FY2025 | US Network Physicians | 1.7 million | 26 |
| 2026-02-26 | FY2025 | US Network Hospitals | over 6,000 | 26 |
| 2026-02-26 | FY2025 | US Federal Government Revenue % 2024 | 11% | 26 |
| 2026-02-26 | FY2025 | US Federal Government Revenue % 2023 | 15% | 26 |
| 2026-02-26 | FY2025 | US Ethnic Minorities % | 40% | 26 |
| 2026-02-26 | FY2025 | Underrepresented-to-White Wage Ratio US | more than 99 cents per dollar | 26 |
| 2026-02-26 | FY2025 | Specialty Pharmacies | 35 licensed pharmacies | 26 |
| 2026-02-26 | FY2025 | Specialist Group Arrangements | approximately 100 | 26 |
| 2026-02-26 | FY2025 | Single Pharmacy Benefit Client Revenue % 2025 | 19% | 26 |
| 2026-02-26 | FY2025 | Single Pharmacy Benefit Client Revenue % 2024 | 16% | 26 |
| 2026-02-26 | FY2025 | Primary Care Value-Based Arrangements | more than 200 | 26 |
| 2026-02-26 | FY2025 | Pharmacy Claims Processing Capacity | over two billion adjusted prescriptions annually | 26 |
| 2026-02-26 | FY2025 | Pharmaceutical Purchases Single Wholesaler % | approximately 50% | 26 |
| 2026-02-26 | FY2025 | markets and jurisdictions | more than 30 | 26 |
| 2026-02-26 | FY2025 | insured segment revenue percentage 2025 | 68% | 26 |
| 2026-02-26 | FY2025 | insured medical customers percentage 2025 | 21% | 26 |
| 2026-02-26 | FY2025 | individual family plans states | 11 states | 26 |
| 2026-02-26 | FY2025 | hospital system hospitals covered | more than 750 | 26 |
| 2026-02-26 | FY2025 | hospital system contracts | more than 200 | 26 |
| 2026-02-26 | FY2025 | home delivery pharmacy locations | 11 licensed pharmacies | 26 |
| 2026-02-26 | FY2025 | home delivery pharmacy fulfillment centers | 4 | 26 |
| 2026-02-26 | FY2025 | healthcare providers relationships | 1.7 million | 26 |
| 2026-02-26 | FY2025 | health system services distribution centers | 4 | 26 |
| 2026-02-26 | FY2025 | health benefits payroll investment percentage | 20% | 26 |
| 2026-02-26 | FY2025 | female to male wage ratio US | more than 99 cents per dollar | 26 |
| 2026-02-26 | FY2025 | female to male wage ratio global | more than 99 cents per dollar | 26 |
| 2026-02-26 | FY2025 | Express Scripts rebate sharing percentage 2025 | over 95% | 26 |
| 2026-02-26 | FY2025 | Express Scripts clients receiving 100 percent rebates | more than two-thirds | 26 |
| 2026-02-26 | FY2025 | Enguide pharmacy locations | 2 licensed pharmacies | 26 |
| 2026-02-26 | FY2025 | Enguide pharmacy fulfillment centers | 1 | 26 |
| 2026-02-26 | FY2025 | dental IFP states | 49 states | 26 |
| 2026-02-26 | FY2025 | customer relationships | 185 million | 26 |
| 2026-02-26 | FY2025 | ASO segment revenue percentage 2025 | 32% | 26 |
| 2026-02-26 | FY2025 | ASO medical customers percentage 2025 | 79% | 26 |
| 2026-02-26 | FY2025 | Unpaid claims and claim expenses | $4,241 | 26 |
| 2026-02-26 | FY2025 | Undrawn committed capacity | $6.5 billion | 26 |
| 2026-02-26 | FY2025 | Total medical customers | 18,118 | 26 |
| 2026-02-26 | FY2025 | Debt to capitalization ratio | 43.0% | 26 |
| 2026-02-05 | 2025-Q4 | Total Pharmacy Customers | 123,603 | 25 |
| 2026-02-05 | 2025-Q4 | Total Medical Customers | 18,118 | 25 |
| 2026-02-05 | 2025-Q4 | Total Customer Relationships | 188,428 | 25 |
| 2026-02-05 | 2025-Q4 | Shareholders' Equity per Share | $158.33 | 25 |
| 2026-02-05 | 2025-Q4 | SG&A Expense Ratio (Q4 2025) | 5.0% | 25 |
| 2026-02-05 | 2025-Q4 | SG&A Expense Ratio (FY 2025) | 5.3% | 25 |
| 2026-02-05 | 2025-Q4 | Dental Customers | 18,438 | 25 |
| 2026-02-05 | 2025-Q4 | Debt-to-Capitalization Ratio | 43.0% | 25 |
| 2026-02-05 | 2025-Q4 | Cigna Healthcare Medical Care Ratio (Q4 2025) | 88.0% | 25 |
| 2026-02-05 | 2025-Q4 | Cigna Healthcare Medical Care Ratio (FY 2025) | 84.4% | 25 |
| 2026-02-05 | 2025-Q4 | Behavioral Care Customers | 28,269 | 25 |
| 2026-02-05 | 2025-Q4 | Adjusted SG&A Expense Ratio (Q4 2025) | 4.7% | 25 |
| 2026-02-05 | 2025-Q4 | Adjusted SG&A Expense Ratio (FY 2025) | 5.0% | 25 |
| 2025-10-30 | 2025-Q3 | Unpaid claims and claim expenses | $4,676 | 23 |
| 2025-10-30 | 2025-Q3 | Total Pharmacy Customers | 122,486 | 24 |
| 2025-10-30 | 2025-Q3 | Total Medical Customers | 18,059 | 24 |
| 2025-10-30 | 2025-Q3 | Total Customer Relationships | 182,490 | 24 |
| 2025-10-30 | 2025-Q3 | Medical customers | 18,059 | 23 |
| 2025-10-30 | 2025-Q3 | Debt-to-capitalization ratio | 44.9% | 23 |
| 2025-10-30 | 2025-Q3 | Cigna Healthcare Medical Care Ratio | 84.8% | 24 |
| 2025-07-31 | 2025-Q2 | Total revenues (3 months) | 67,178 (USD in millions) | 21 |
| 2025-07-31 | 2025-Q2 | Total revenues (6 months) | 132,680 (USD in millions) | 21 |
| 2025-07-31 | 2025-Q2 | Total income taxes (3 months) | 389 (USD in millions) | 21 |
| 2025-07-31 | 2025-Q2 | Total income taxes (6 months) | 628 (USD in millions) | 21 |
| 2025-07-31 | 2025-Q2 | Shareholders' net income (3 months) | 1,532 | 21 |
| 2025-07-31 | 2025-Q2 | Shareholders' net income (6 months) | 2,855 | 21 |
| 2025-07-31 | 2025-Q2 | Premiums (3 months) | 9,156 | 21 |
| 2025-07-31 | 2025-Q2 | Premiums (6 months) | 21,892 | 21 |
| 2025-07-31 | 2025-Q2 | Pharmacy revenues (3 months) | 53,649 (USD in millions) | 21 |
| 2025-07-31 | 2025-Q2 | Pharmacy revenues six months | 102,282 (USD in millions) | 21 |
| 2025-07-31 | 2025-Q2 | Pharmacy and other service costs three months | 53,268 (USD in millions) | 21 |
| 2025-07-31 | 2025-Q2 | Pharmacy and other service costs six months | 101,666 (USD in millions) | 21 |
| 2025-07-31 | 2025-Q2 | Net investment income three months | 236 (USD in millions) | 21 |
| 2025-07-31 | 2025-Q2 | Net investment income six months | 474 (USD in millions) | 21 |
| 2025-07-31 | 2025-Q2 | Net investment gains/losses three months | 52 (USD in millions) | 21 |
| 2025-07-31 | 2025-Q2 | Net investment gains/losses six months | 50 (USD in millions) | 21 |
| 2025-07-31 | 2025-Q2 | Net income three months | 1,632 (USD in millions) | 21 |
| 2025-07-31 | 2025-Q2 | Net income six months | 3,041 (USD in millions) | 21 |
| 2025-07-31 | 2025-Q2 | Net income attributable to noncontrolling interests three months | 100 (USD in millions) | 21 |
| 2025-07-31 | 2025-Q2 | Net income attributable to noncontrolling interests six months | 186 (USD in millions) | 21 |
| 2025-07-31 | 2025-Q2 | Medical customers thousands | 18,046 | 21 |
| 2025-07-31 | 2025-Q2 | Medical costs and other benefit expenses three months | 7,749 (USD in millions) | 21 |
| 2025-07-31 | 2025-Q2 | Medical costs and other benefit expenses six months | 18,247 (USD in millions) | 21 |
| 2025-07-31 | 2025-Q2 | Interest expense and other three months | (337) | 21 |
| 2025-07-31 | 2025-Q2 | Interest expense and other six months | (699) | 21 |
| 2025-07-31 | 2025-Q2 | Income from operations three months | 2,306 | 21 |
| 2025-07-31 | 2025-Q2 | Income from operations six months | 4,277 | 21 |
| 2025-07-31 | 2025-Q2 | Income before income taxes three months | 2,021 (USD in millions) | 21 |
| 2025-07-31 | 2025-Q2 | Income before income taxes six months | 3,669 (USD in millions) | 21 |
| 2025-07-31 | 2025-Q2 | Gain (Loss) on Sale of Businesses (3M) | – | 21 |
| 2025-07-31 | 2025-Q2 | Gain (Loss) on Sale of Businesses (6M) | 41 | 21 |
| 2025-07-31 | 2025-Q2 | Fees and Other Revenues (3M) | 4,137 (USD in millions) | 21 |
| 2025-07-31 | 2025-Q2 | Fees and Other Revenues (6M) | 8,032 (USD in millions) | 21 |
| 2025-07-31 | 2025-Q2 | Effective Tax Rate (3M) | 19.2 % | 21 |
| 2025-07-31 | 2025-Q2 | Effective Tax Rate (6M) | 17.1 % | 21 |
| 2025-07-31 | 2025-Q2 | Consolidated Effective Tax Rate 2024 (3M) | 18.1 % | 21 |
| 2025-07-31 | 2025-Q2 | Consolidated Effective Tax Rate 2024 (6M) | 31.5 % | 21 |
| 2025-07-31 | 2025-Q2 | Total Pharmacy Customers | 121,892 | 22 |
| 2025-07-31 | 2025-Q2 | Total medical customers | 18,046 | 22 |
| 2025-07-31 | 2025-Q2 | Total Customer Relationships | 182,236 | 22 |
| 2025-07-31 | 2025-Q2 | Cigna Healthcare Medical Care Ratio | 83.2% | 22 |
| 2025-05-02 | 2025-Q1 | Unpaid claims and claim expenses | 4,508 (USD in millions) | 19 |
| 2025-05-02 | 2025-Q1 | U.S. Healthcare Medical Customers | 16,364 | 20 |
| 2025-05-02 | 2025-Q1 | Total Pharmacy Customers | 122,283 | 20 |
| 2025-05-02 | 2025-Q1 | Total Medical Customers | 18,043 | 20 |
| 2025-05-02 | 2025-Q1 | Total Customer Relationships | 182,208 | 20 |
| 2025-05-02 | 2025-Q1 | SG&A Expense Ratio | 6.4% | 20 |
| 2025-05-02 | 2025-Q1 | Medical customers | 18,043 | 19 |
| 2025-05-02 | 2025-Q1 | International Health Medical Customers | 1,679 | 20 |
| 2025-05-02 | 2025-Q1 | Evernorth Health Services Margin, Pre-Tax | 2.7% | 20 |
| 2025-05-02 | 2025-Q1 | Dental Customers | 18,466 | 20 |
| 2025-05-02 | 2025-Q1 | Debt-to-capitalization ratio | 43.1% | 19 |
| 2025-05-02 | 2025-Q1 | Cigna Healthcare Medical Care Ratio | 82.2% | 20 |
| 2025-05-02 | 2025-Q1 | Cigna Healthcare Margin, Pre-Tax | 8.9% | 20 |
| 2025-05-02 | 2025-Q1 | Behavioral Care Customers | 23,416 | 20 |
| 2025-05-02 | 2025-Q1 | Adjusted SG&A Expense Ratio | 5.8% | 20 |
| 2025-02-27 | FY2024 | Voluntary Turnover Rate | approximately 9% | 18 |
| 2025-02-27 | FY2024 | U.S. Physician Network | approximately 1.8 million | 18 |
| 2025-02-27 | FY2024 | US Patents | over 480 | 18 |
| 2025-02-27 | FY2024 | U.S. Federal Government Revenue 2024 (%) | approximately 11% | 18 |
| 2025-02-27 | FY2024 | U.S. Federal Government Revenue 2023 (%) | 15% | 18 |
| 2025-02-27 | FY2024 | U.S. Federal Government Revenue 2022 (%) | 14% | 18 |
| 2025-02-27 | FY2024 | Specialty Pharmacies | 35 licensed pharmacies | 18 |
| 2025-02-27 | FY2024 | single pharmacy client revenue percentage | approximately 16% | 18 |
| 2025-02-27 | FY2024 | settlement annuity guaranteed payments percentage | approximately 12% | 18 |
| 2025-02-27 | FY2024 | retail pharmacy networks | national and regional network options | 18 |
| 2025-02-27 | FY2024 | provider value based arrangements specialist | approximately 100 | 18 |
| 2025-02-27 | FY2024 | provider value based arrangements primary care | more than 200 | 18 |
| 2025-02-27 | FY2024 | payroll invested in benefits percentage | approximately 19% | 18 |
| 2025-02-27 | FY2024 | medicare supplement plans states | 48 states and the District of Columbia | 18 |
| 2025-02-27 | FY2024 | medicare advantage plans states | 29 states and the District of Columbia | 18 |
| 2025-02-27 | FY2024 | insured segment revenue percentage | approximately 74% | 18 |
| 2025-02-27 | FY2024 | insured medical customers percentage | 26% | 18 |
| 2025-02-27 | FY2024 | ifp plans states | 11 states | 18 |
| 2025-02-27 | FY2024 | hospitals in contracts | more than 800 | 18 |
| 2025-02-27 | FY2024 | hospital system contracts | more than 200 | 18 |
| 2025-02-27 | FY2024 | hospital network | over 6,000 | 18 |
| 2025-02-27 | FY2024 | home delivery pharmacies | 13 licensed pharmacies, including 4 fulfillment pharmacies | 18 |
| 2025-02-27 | FY2024 | ethnic minority pay equity us | more than 99 cents | 18 |
| 2025-02-27 | FY2024 | dental ifp plans states | 49 states | 18 |
| 2025-02-27 | FY2024 | customer patient relationships | approximately 182 million | 18 |
| 2025-02-27 | FY2024 | cigna ventures commitment | 700 million | 18 |
| 2025-02-27 | FY2024 | centene rebates shared percentage | over 95% | 18 |
| 2025-02-27 | FY2024 | centene clients 100pct rebates percentage | more than two-thirds | 18 |
| 2025-02-27 | FY2024 | ASO Segment Revenue % | approximately 26% | 18 |
| 2025-02-27 | FY2024 | ASO Medical Customers % | 74% | 18 |
| 2025-02-27 | FY2024 | Adjusted Prescriptions Annually | over 2 billion | 18 |
| 2025-02-27 | FY2024 | Valuation Allowances 2024 | $2,332 million | 18 |
| 2025-02-27 | FY2024 | Valuation Allowances 2023 | $1,498 million | 18 |
| 2025-02-27 | FY2024 | Unpaid Claims Net 2024 | $4,859 million | 18 |
| 2025-02-27 | FY2024 | Unpaid Claims Net 2023 | $4,856 million | 18 |
| 2025-02-27 | FY2024 | Unpaid Claims Gross 2024 | $5,018 million | 18 |
| 2025-02-27 | FY2024 | Unpaid Claims Gross 2023 | $5,092 million | 18 |
| 2025-02-27 | FY2024 | Undrawn Committed Capacity | $6.5 billion | 18 |
| 2025-02-27 | FY2024 | Uncertain Tax Positions | $1.5 billion | 18 |
| 2025-02-27 | FY2024 | Total Share Repurchase Authority | $10.3 billion | 18 |
| 2025-02-27 | FY2024 | Tax Position Balances 2024 | $1,477 million | 18 |
| 2025-02-27 | FY2024 | Tax Position Balances 2023 | $1,399 million | 18 |
| 2025-02-27 | FY2024 | Subsidiary Borrowing Capacity | $1.8 billion | 18 |
| 2025-02-27 | FY2024 | Shares Repurchased 2025 YTD | 3.0 million | 18 |
| 2025-02-27 | FY2024 | Shares Repurchased 2024 | 20.9 million | 18 |
| 2025-02-27 | FY2024 | Shares Repurchased 2023 | 7.8 million | 18 |
| 2025-02-27 | FY2024 | Share Repurchase Amount 2025 YTD | $901 million | 18 |
| 2025-02-27 | FY2024 | Share Repurchase Amount 2024 | $7.0 billion | 18 |
| 2025-02-27 | FY2024 | Share Repurchase Amount 2023 | $2.3 billion | 18 |
| 2025-02-27 | FY2024 | Service Commitments 2025 | $0.7 billion | 18 |
| 2025-02-27 | FY2024 | Remaining Share Repurchase Authority | $9.4 billion | 18 |
| 2025-02-27 | FY2024 | Remaining Commercial Paper Capacity | $5.6 billion | 18 |
| 2025-02-27 | FY2024 | Purchase Obligations Total | $4.2 billion | 18 |
| 2025-02-27 | FY2024 | Purchase Obligations Next 12 Months | $1.6 billion | 18 |
| 2025-02-27 | FY2024 | Potential Tax Payments | $1.0 billion | 18 |
| 2025-02-27 | FY2024 | Parent Company Cash | $0.8 billion | 18 |
| 2025-02-27 | FY2024 | Other Long Term Investments | $4.6 billion | 18 |
| 2025-02-27 | FY2024 | Medical customers | 19,147 | 18 |
| 2025-02-27 | FY2024 | Long Term Debt Scheduled Payments | $48.5 billion | 18 |
| 2025-02-27 | FY2024 | Long Term Debt Due 2025 | $3.5 billion | 18 |
| 2025-02-27 | FY2024 | Investment Grade Debt Securities | $8.1 billion | 18 |
| 2025-02-27 | FY2024 | Investment Commitments 2025 | $0.9 billion | 18 |
| 2025-02-27 | FY2024 | Investment Commitments | $2.7 billion | 18 |
| 2025-02-27 | FY2024 | HCSC Transaction Initial Price | $3.3 billion | 18 |
| 2025-02-27 | FY2024 | Future Service Commitments | $1.5 billion | 18 |
| 2025-02-27 | FY2024 | Expected Capex 2025 | $1.4 billion | 18 |
| 2025-02-27 | FY2024 | Dividends from US Subsidiaries 2024 | $2.4 billion | 18 |
| 2025-02-27 | FY2024 | Dividends from US Subsidiaries 2023 | $1.2 billion | 18 |
| 2025-02-27 | FY2024 | Debt to Capitalization Ratio 2024 | 43.8% | 18 |
| 2025-02-27 | FY2024 | Debt to Capitalization Ratio 2023 | 40.1% | 18 |
| 2025-02-27 | FY2024 | Debt Securities Portfolio | $9.4 billion | 18 |
| 2025-02-27 | FY2024 | Debt Securities 2023 | $9.9 billion | 18 |
| 2025-02-27 | FY2024 | Commercial Paper Outstanding | $0.9 billion | 18 |
| 2025-02-27 | FY2024 | Commercial Mortgage Loan Portfolio | $1.4 billion | 18 |
| 2025-02-27 | FY2024 | China Joint Venture Investment Portfolio | $15.6 billion | 18 |
| 2025-02-27 | FY2024 | Cash and Short-Term Investments | $7.6 billion | 18 |
| 2025-02-27 | FY2024 | Capital Expenditures 2024 | $1.4 billion | 18 |
| 2025-02-27 | FY2024 | Capital Expenditures 2023 | $1.6 billion | 18 |
| 2025-02-27 | FY2024 | Below Investment Grade Debt Securities | $1.3 billion | 18 |
| 2025-01-30 | 2024-Q4 | Total Pharmacy Customers | 118,304 | 17 |
| 2025-01-30 | 2024-Q4 | Total Medical Customers | 19,147 | 17 |
| 2025-01-30 | 2024-Q4 | Total Customer Relationships | 182,212 | 17 |
| 2025-01-30 | 2024-Q4 | Specialty and Care Services Adjusted Revenues, Q4 2024 | 23,471 (USD in millions) | 17 |
| 2025-01-30 | 2024-Q4 | Specialty and Care Services Adjusted Revenues, Full Year 2024 | 90,333 (USD in millions) | 17 |
| 2025-01-30 | 2024-Q4 | Specialty and Care Services Adjusted Income from Operations Pre-Tax, Q4 2024 | 948 | 17 |
| 2025-01-30 | 2024-Q4 | Specialty and Care Services Adjusted Income from Operations Pre-Tax, Full Year 2024 | 3,424 | 17 |
| 2025-01-30 | 2024-Q4 | Pharmacy Benefit Services Adjusted Revenues, Q4 2024 | 30,273 (USD in millions) | 17 |
| 2025-01-30 | 2024-Q4 | Pharmacy Benefit Services Adjusted Revenues, Full Year 2024 | 111,822 (USD in millions) | 17 |
| 2025-01-30 | 2024-Q4 | Pharmacy Benefit Services Adjusted Income from Operations Pre-Tax, Q4 2024 | 1,198 | 17 |
| 2025-01-30 | 2024-Q4 | Pharmacy Benefit Services Adjusted Income from Operations Pre-Tax, Full Year 2024 | 3,577 | 17 |
| 2025-01-30 | 2024-Q4 | Evernorth Health Services Adjusted Revenues, Q4 2024 | 53,744 (USD in millions) | 17 |
| 2025-01-30 | 2024-Q4 | Evernorth Health Services Adjusted Revenues, Full Year 2024 | 202,155 (USD in millions) | 17 |
| 2025-01-30 | 2024-Q4 | Evernorth Health Services Adjusted Income from Operations Pre-Tax, Q4 2024 | 2,146 | 17 |
| 2025-01-30 | 2024-Q4 | Evernorth Health Services Adjusted Income from Operations Pre-Tax, Full Year 2024 | 7,001 | 17 |
| 2025-01-30 | 2024-Q4 | Cigna Healthcare MCR, Q4 2024 | 87.9% | 17 |
| 2025-01-30 | 2024-Q4 | Cigna Healthcare MCR, Full Year 2024 | 83.2% | 17 |
| 2025-01-30 | 2024-Q4 | Cigna Healthcare Adjusted Revenues, Q4 2024 | 13,331 (USD in millions) | 17 |
| 2025-01-30 | 2024-Q4 | Cigna Healthcare Adjusted Revenues, Full Year 2024 | 52,914 (USD in millions) | 17 |
| 2025-01-30 | 2024-Q4 | Cigna Healthcare Adjusted Income from Operations Pre-Tax, Q4 2024 | 511 | 17 |
| 2025-01-30 | 2024-Q4 | Cigna Healthcare Adjusted Income from Operations Pre-Tax, Full Year 2024 | 4,229 | 17 |
| 2024-10-31 | 2024-Q3 | Pharmacy claim volume | 531 | 15 |
| 2024-10-31 | 2024-Q3 | Medical customers | 19,048 | 15 |
| 2024-10-31 | 2024-Q3 | Adjusted revenues | 63,699 (USD millions) | 15 |
| 2024-10-31 | 2024-Q3 | Total Pharmacy Customers | 119,996 | 16 |
| 2024-10-31 | 2024-Q3 | Total Medical Customers | 19,048 | 16 |
| 2024-10-31 | 2024-Q3 | Total Customer Relationships | 183,514 | 16 |
| 2024-10-31 | 2024-Q3 | SG&A Expense Ratio | 5.6% | 16 |
| 2024-10-31 | 2024-Q3 | Medicare Part D Customers | 2,557 | 16 |
| 2024-10-31 | 2024-Q3 | Dental Customers | 18,251 | 16 |
| 2024-10-31 | 2024-Q3 | Cigna Healthcare Medical Care Ratio | 82.8% | 16 |
| 2024-10-31 | 2024-Q3 | Behavioral Care Customers | 23,662 | 16 |
| 2024-10-31 | 2024-Q3 | Adjusted SG&A Expense Ratio | 5.5% | 16 |
| 2024-08-01 | 2024-Q2 | Unpaid claims and claim expenses Cigna Healthcare | 5202 (USD in millions) | 13 |
| 2024-08-01 | 2024-Q2 | Undrawn revolving credit capacity | 6500 | 13 |
| 2024-08-01 | 2024-Q2 | Total Pharmacy Customers | 122,470 | 14 |
| 2024-08-01 | 2024-Q2 | Total Medical Customers | 19,043 | 14 |
| 2024-08-01 | 2024-Q2 | Total Customer Relationships | 186,232 | 14 |
| 2024-08-01 | 2024-Q2 | Shareholders' Equity per Share | $147.87 | 14 |
| 2024-08-01 | 2024-Q2 | Shareholders' Equity | $41,332 | 14 |
| 2024-08-01 | 2024-Q2 | SG&A Expense Ratio | 6.1% | 14 |
| 2024-08-01 | 2024-Q2 | Medicare Part D Customers | 2,564 | 14 |
| 2024-08-01 | 2024-Q2 | Medical customers | 19043 | 13 |
| 2024-08-01 | 2024-Q2 | Dental Customers | 18,339 | 14 |
| 2024-08-01 | 2024-Q2 | Debt-to-Capitalization Ratio | 43.6% | 14 |
| 2024-08-01 | 2024-Q2 | Debt to capitalization ratio | 43.6% | 13 |
| 2024-08-01 | 2024-Q2 | Commercial paper outstanding | 790 | 13 |
| 2024-08-01 | 2024-Q2 | Cigna Healthcare Medical Care Ratio | 82.3% | 14 |
| 2024-08-01 | 2024-Q2 | Cash and short-term investments | 7000 (USD in millions) | 13 |
| 2024-08-01 | 2024-Q2 | Behavioral Care Customers | 23,816 | 14 |
| 2024-08-01 | 2024-Q2 | Adjusted SG&A Expense Ratio | 6.0% | 14 |
| 2024-05-02 | 2024-Q1 | Total Pharmacy Customers | 122,767 | 12 |
| 2024-05-02 | 2024-Q1 | Total Medical Customers | 19,184 | 12 |
| 2024-05-02 | 2024-Q1 | Total Customer Relationships | 186,753 | 12 |
| 2024-05-02 | 2024-Q1 | Shareholders' Equity per Share | 145.00 | 12 |
| 2024-05-02 | 2024-Q1 | Shareholders' Equity | 41,181 | 12 |
| 2024-05-02 | 2024-Q1 | Pre-tax adjusted margin Evernorth | 2.9% | 11 |
| 2024-05-02 | 2024-Q1 | Pre-tax adjusted margin Cigna Healthcare | 10.1% | 11 |
| 2024-05-02 | 2024-Q1 | Medicare Part D Customers | 2,558 | 12 |
| 2024-05-02 | 2024-Q1 | Medical customers | 19184 | 11 |
| 2024-05-02 | 2024-Q1 | Medical care ratio Cigna Healthcare | 79.9% | 11 |
| 2024-05-02 | 2024-Q1 | Dental Customers | 18,443 | 12 |
| 2024-05-02 | 2024-Q1 | Cigna Healthcare MCR | 79.9% | 12 |
| 2024-05-02 | 2024-Q1 | Behavioral Care Customers | 23,801 | 12 |
| 2024-05-02 | 2024-Q1 | Adjusted Expense Ratio Evernorth | 2.1% | 11 |
| 2024-05-02 | 2024-Q1 | Adjusted Expense Ratio Cigna Healthcare | 20.5% | 11 |
| 2024-02-29 | FY2023 | Pre-Tax Adjusted Margin Other Operations | 16.1% | 10 |
| 2024-02-29 | FY2023 | Pre-Tax Adjusted Margin Evernorth | 4.2% | 10 |
| 2024-02-29 | FY2023 | Pre-Tax Adjusted Margin Cigna | 8.7% | 10 |
| 2024-02-29 | FY2023 | Overall Generic Fill Rate | 86.7% | 10 |
| 2024-02-29 | FY2023 | Network Generic Fill Rate | 86.9% | 10 |
| 2024-02-29 | FY2023 | Medical Care Ratio Cigna | 81.3% | 10 |
| 2024-02-29 | FY2023 | Home Delivery Generic Fill Rate | 85.3% | 10 |
| 2024-02-29 | FY2023 | Adjusted Expense Ratio Evernorth | 2.2% | 10 |
| 2024-02-29 | FY2023 | Adjusted Expense Ratio Cigna | 21.6% | 10 |
| 2024-02-29 | FY2023 | Medical customers | 19,780 | 10 |
| 2024-02-02 | 2023-Q4 | U.S. Healthcare | 18.170 million | 9 |
| 2024-02-02 | 2023-Q4 | Total Pharmacy Customers | 98.6 million | 9 |
| 2024-02-02 | 2023-Q4 | Total Medical Customers | 19.8 million | 9 |
| 2024-02-02 | 2023-Q4 | Total Customer Relationships | 164.399 million | 9 |
| 2024-02-02 | 2023-Q4 | Medicare Part D | 2.550 million | 9 |
| 2024-02-02 | 2023-Q4 | International Health | 1.610 million | 9 |
| 2024-02-02 | 2023-Q4 | Dental | 18.543 million | 9 |
| 2024-02-02 | 2023-Q4 | Debt-to-Capitalization Ratio (December 31, 2023) | 40.1% | 9 |
| 2024-02-02 | 2023-Q4 | Cigna Healthcare Medical Care Ratio (Q4 2023) | 82.2% | 9 |
| 2024-02-02 | 2023-Q4 | Cigna Healthcare Medical Care Ratio (Full Year 2023) | 81.3% | 9 |
| 2024-02-02 | 2023-Q4 | Behavioral Care | 24.956 million | 9 |
| 2023-11-02 | 2023-Q3 | Total Revenues | $49,048 | 7 |
| 2023-11-02 | 2023-Q3 | Shareholders Net Income | $1,408 | 7 |
| 2023-11-02 | 2023-Q3 | Medical customers | 19,607 | 7 |
| 2023-11-02 | 2023-Q3 | Adjusted revenues | $49,078 | 7 |
| 2023-11-02 | 2023-Q3 | Total Pharmacy Customers | 98,325 | 8 |
| 2023-11-02 | 2023-Q3 | Total Medical Customers | 19,607 | 8 |
| 2023-11-02 | 2023-Q3 | Total Customer Relationships | 164,169 | 8 |
| 2023-11-02 | 2023-Q3 | Shareholders' Equity per Share | $155.54 | 8 |
| 2023-11-02 | 2023-Q3 | Evernorth Health Services Adjusted Margin, Pre-Tax | 4.4% | 8 |
| 2023-11-02 | 2023-Q3 | Debt-to-Capitalization Ratio | 40.5% | 8 |
| 2023-11-02 | 2023-Q3 | Cigna Healthcare Medical Care Ratio | 80.5% | 8 |
| 2023-11-02 | 2023-Q3 | Cigna Healthcare Adjusted Margin, Pre-Tax | 9.6% | 8 |
| 2023-11-02 | 2023-Q3 | Adjusted SG&A Expense Ratio | 7.3% | 8 |
| 2023-08-03 | 2023-Q2 | Unpaid Claims and Claim Expenses - Cigna Healthcare | 5,336 (USD millions) | 5 |
| 2023-08-03 | 2023-Q2 | Total Pharmacy Customers | 98,638 | 6 |
| 2023-08-03 | 2023-Q2 | Total Medical Customers | 19,506 | 6 |
| 2023-08-03 | 2023-Q2 | Total Customer Relationships | 165,703 | 6 |
| 2023-08-03 | 2023-Q2 | SG&A Expense Ratio | 7.1% | 6 |
| 2023-08-03 | 2023-Q2 | Medical customers | 19,506 | 5 |
| 2023-08-03 | 2023-Q2 | Evernorth Adjusted Margin, Pre-Tax | 4.0% | 6 |
| 2023-08-03 | 2023-Q2 | Debt-to-capitalization ratio | 41.9% | 6 |
| 2023-08-03 | 2023-Q2 | Cigna Healthcare MCR | 81.2% | 6 |
| 2023-08-03 | 2023-Q2 | Cigna Healthcare Adjusted Margin, Pre-Tax | 9.2% | 6 |
| 2023-05-05 | 2023-Q1 | Total Pharmacy Customers | 98,749 | 4 |
| 2023-05-05 | 2023-Q1 | Total Medical Customers | 19,473 | 4 |
| 2023-05-05 | 2023-Q1 | Total Customer Relationships | 166,384 | 4 |
| 2023-05-05 | 2023-Q1 | Share Repurchases YTD | 3.7 million shares | 4 |
| 2023-05-05 | 2023-Q1 | Medicare Part D Customers | 2,541 | 4 |
| 2023-05-05 | 2023-Q1 | Medical customers | 19,473 | 3 |
| 2023-05-05 | 2023-Q1 | Diluted Earnings Per Share | 4.24 | 3 |
| 2023-05-05 | 2023-Q1 | Dental Customers | 18,731 | 4 |
| 2023-05-05 | 2023-Q1 | Debt-to-Capitalization Ratio | 42.2% | 4 |
| 2023-05-05 | 2023-Q1 | Cigna Healthcare MCR | 81.3% | 4 |
| 2023-05-05 | 2023-Q1 | Behavioral Care Customers | 26,890 | 4 |
| 2023-05-05 | 2023-Q1 | Adjusted Revenues | 46,479 (USD in millions) | 3 |
Guidance Tracking (latest per metric/period · 25/50)#
All management forecasts (guidance) and their later outcome. Types: fiscal-year targets as well as quarterly/half-year targets; per metric and period the most recent statement applies, older versions can be expanded. The status is checked automatically against the actuals reported later: open (period still running), met, beaten, missed. For ranges (“X to Y”) reaching the range counts. Logged neutrally, no estimate of our own, no assessment.
| For period | Guided on | Metric | Guided | Verdict | Direction | Source |
|---|---|---|---|---|---|---|
| FY2026 | 2026-02-05 | EPS (non-GAAP) | 30.45 | pending | raised | 30 |
| FY2026 | 2026-02-05 | Tax rate | ~19% | pending | initiated | 25 |
| FY2026 | 2026-02-05 | Capex | ~1,300 | pending | initiated | 25 |
| FY2026 | 2026-02-05 | Evernorth Adjusted Income from Operations, Pre-Tax | 6,900 | pending | confirmed | 28 |
| FY2026 | 2026-02-05 | Cigna Healthcare Adjusted Income from Operations, Pre-Tax | 4,525 | pending | raised | 28 |
| FY2026 | 2026-02-05 | Cigna Healthcare Medical Care Ratio | 83.7–84.7% | pending | confirmed | 28 |
| FY2026 | 2026-02-05 | Adjusted Income from Operations | 7,950 | pending | initiated | 25 |
| FY2026 | 2026-02-05 | Adjusted Revenues | ~280,000 | pending | initiated | 25 |
| FY2026 | 2026-02-05 | Adjusted SG&A Expense Ratio | ~5% | pending | initiated | 25 |
| FY2026 | 2026-02-05 | Cash Flow from Operations | ~9,000 | pending | initiated | 25 |
| FY2026 | 2026-02-05 | Shareholder Dividends | ~1,600 | pending | initiated | 25 |
| FY2026 | 2026-02-05 | Total Medical Customers | ~18.1 | pending | initiated | 25 |
| FY2025 | 2025-05-02 | EPS (non-GAAP) | 29.6 | – | confirmed | 24 |
| FY2025 | 2025-05-02 | Evernorth Adjusted Income from Operations, Pre-Tax | 7,200 | – | confirmed | 22 |
| FY2025 | 2025-05-02 | Cigna Healthcare Adjusted Income from Operations, Pre-Tax | 4,125 | – | confirmed | 22 |
| FY2025 | 2025-05-02 | Cigna Healthcare Medical Care Ratio | 83.2–84.2% | – | confirmed | 22 |
| 2025-Q4 | 2025-01-30 | Tax rate | ~19% | – | initiated | 17 |
| 2025-Q4 | 2025-01-30 | Capex | ~1,400 | – | initiated | 17 |
| 2025-Q4 | 2025-01-30 | Adjusted Income from Operations | 7,900 | – | raised | 17 |
| 2025-Q4 | 2025-01-30 | Adjusted Revenues | 252,000 | – | initiated | 17 |
| 2025-Q4 | 2025-01-30 | Adjusted SG&A Expense Ratio | ~5.4% | – | initiated | 17 |
| 2025-Q4 | 2025-01-30 | Cash Flow from Operations | ~10,000 | – | initiated | 17 |
| 2025-Q4 | 2025-01-30 | Shareholder Dividends | ~1,600 | – | initiated | 17 |
| 2025-Q4 | 2025-01-30 | Weighted Average Shares Outstanding | 266–270 | – | initiated | 17 |
| 2025-Q4 | 2025-01-30 | Total Medical Customers | ~18.1 | – | initiated | 17 |
| FY2024 | 2024-05-02 | Adjusted Income from Operations, Pre-Tax (Evernorth) | 7,000 | – | confirmed | 12 |
| FY2024 | 2024-05-02 | Adjusted Income from Operations, Pre-Tax (Cigna Healthcare) | 4,775 | – | raised | 12 |
| FY2024 | 2024-05-02 | Medical Care Ratio | 81.7–82.5% | – | confirmed | 12 |
| FY2024 | 2024-02-02 | EPS (non-GAAP) | 28.4 | – | confirmed | 16 |
| FY2024 | 2024-02-02 | Tax rate | 20.5–21% | – | confirmed | 12 |
| FY2024 | 2024-02-02 | Capex | ~1,500 | – | confirmed | 9 |
| FY2024 | 2024-02-02 | Evernorth Adjusted Income from Operations, Pre-Tax | 7,000 | – | confirmed | 16 |
| FY2024 | 2024-02-02 | Cigna Healthcare Adjusted Income from Operations, Pre-Tax | 4,775 | – | confirmed | 16 |
| FY2024 | 2024-02-02 | Cigna Healthcare Medical Care Ratio | 81.7–82.5% | – | confirmed | 16 |
| FY2024 | 2024-02-02 | Adjusted Income from Operations | 8,065 | – | raised | 12 |
| FY2024 | 2024-02-02 | Adjusted Revenues | 235,000 | – | confirmed | 12 |
| FY2024 | 2024-02-02 | Adjusted SG&A Expense Ratio | ~6.1% | – | confirmed | 12 |
| FY2024 | 2024-02-02 | Cash Flow from Operations | 11,000 | – | confirmed | 12 |
| FY2024 | 2024-02-02 | Weighted Average Shares Outstanding | 282–286 | – | confirmed | 12 |
| FY2024 | 2024-02-02 | Total Medical Customers | ~19.3 | – | confirmed | 12 |
| FY2024 | 2024-02-02 | Shareholder Dividends | ~1,550 | – | confirmed | 9 |
| FY2023 | 2023-11-02 | Cash Flow from Operations | 10,500 | – | raised | 8 |
| FY2023 | 2023-11-02 | Total Medical Customer Growth | 1,600,000 | – | raised | 8 |
| FY2023 | 2023-08-03 | Adjusted Revenues | 192,000 | – | raised | 8 |
| FY2023 | 2023-05-05 | Adjusted Income from Operations, Pre-Tax | 6,400 | – | initiated | 8 |
| FY2023 | 2023-02-03 | EPS (non-GAAP) | 24.75 | – | raised | 8 |
| FY2023 | 2023-02-03 | Tax rate | 21–21.5% | – | confirmed | 1 |
| FY2023 | 2023-02-03 | Adjusted Income from Operations | 7,360 | – | confirmed | 6 |
| FY2023 | 2023-02-03 | Medical Care Ratio | 81.5–82% | – | confirmed | 8 |
| FY2023 | 2023-02-03 | Adjusted SG&A Expense Ratio | ~7.3% | – | confirmed | 1 |
Development#
A condensed summary per reporting period as running text: what changed operationally, which drivers management names, how earnings and cash flow developed. Most recent period first, grouped by year; each text is written from the original report of that period, superscript numbers lead to the source.
FY2026
The Cigna Group reported total revenues of $68.5 billion in Q1 2026 (+5% year-over-year) and $71.7 billion in Q2 2026 (+7%), with growth in both periods driven by Evernorth Health Services and, in Q2, also Cigna Healthcare 28 30. Shareholders' net income rose 25% in Q1 to $1,654 million and 8% in Q2 to $1,660 million, while adjusted income from operations per share increased 12% and 6% respectively, supported by two upward revisions to full-year guidance reaching at least $30.45 per share by July 2026 28 30. The HCSC transaction–completed March 19, 2025, divesting Medicare Advantage and related businesses–reduced Cigna Healthcare premiums 23% year-over-year in Q1 2026 and lowered the medical care ratio by 240 basis points to 79.8% primarily as a base effect of that divestiture, while Cigna Healthcare adjusted income from operations increased 18% in Q1 and 17% in Q2 driven by premium rate increases and improved U.S. Employer margins 27 29 30. In April 2026, the company announced a planned exit from the Individual and Family Plans medical business effective January 1, 2027 30. Within Evernorth Health Services, pharmacy revenues grew 11% in Q1 and 7% in Q2, though Pharmacy Benefit Services adjusted income from operations declined 28% in Q1 and 27% in Q2, reflecting expected lower contributions from large client relationships and client-focused initiatives 27 28 29 30.
FY2025
The Cigna Group reported full-year 2025 revenues of $274.9 billion, an increase of 11% year-over-year, driven primarily by growth in Evernorth Health Services, where pharmacy revenues rose 17% to $216,672 million (26). On March 19, 2025, the company completed the divestiture of its Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses to Health Care Service Corporation for $4.9 billion in cash proceeds, reducing total medical customers by 5% to 18,118 thousand (26). Shareholders' net income increased 73% to $5,957 million ($22.18 per share), primarily reflecting the absence of a non-cash impairment of VillageMD equity securities recorded in 2024; on an adjusted basis, income from operations increased 4% to $8,014 million ($29.84 per share) (26). The Cigna Healthcare segment's medical care ratio rose 120 basis points to 84.4% for the full year, primarily driven by the Individual and Family Plans business (26). In Q3 2025, Evernorth Health Services announced a transformational rebate-free pharmacy benefit model, and the company subsequently established a 2026 adjusted income from operations outlook of at least $7.950 billion ($30.25 per share) (24, 25).
FY2024
The Cigna Group reported FY2024 total revenues of $247.1 billion, a 27% increase from 2023, driven primarily by 32% growth in Evernorth Health Services following the onboarding of Centene Corporation at the start of the year and strong specialty volume growth across pharmacy and specialty businesses 17 18. Adjusted income from operations rose 4% to $7.7 billion ($27.33 per diluted share), as Evernorth Health Services earnings grew 9% while Cigna Healthcare adjusted income from operations declined 6% due to a higher medical care ratio 17. Shareholders' net income of $3.4 billion ($12.12 per diluted share) was materially reduced by $2.7 billion in aggregate non-cash after-tax investment losses from successive impairments of VillageMD equity securities recorded across 2024 17. In January 2024, the Company entered a definitive agreement to divest its Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses to Health Care Service Corporation for approximately $3.7 billion, with closing expected in Q1 2025 17 18. The Cigna Healthcare medical care ratio increased 190 basis points to 83.2% for the full year, primarily driven by higher stop loss medical costs 17 18.
FY2023
The Cigna Group reported full-year 2023 total revenues of $195.3 billion, up from $180.5 billion in 2022, with Evernorth Health Services contributing adjusted revenues of $153.5 billion and Cigna Healthcare contributing adjusted revenues of $51.2 billion (9, 10). Adjusted income from operations reached $7.4 billion, or $25.09 per share, compared with $7.3 billion, or $23.36 per share, in 2022, driven by higher earnings in both reportable segments (9). Shareholders' net income of $5.16 billion ($17.39 per share) was reduced by an estimated loss recognized in connection with the definitive agreement to sell Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses to Health Care Service Corporation for $3.3 billion cash, partially offset by foreign deferred tax benefits (10, 18). Medical customers grew 10% to 19.8 million and pharmacy customers grew 5% to 98.6 million at December 31, 2023, while the company repurchased approximately $2.3 billion in shares and declared a 14% increase in the quarterly dividend (9). Strategic investments during 2023 included a $2.7 billion preferred equity stake in VillageMD and a minority interest in CarepathRx Health Systems Solutions, alongside capital expenditures of $1.6 billion (10).
Sources: official investor relations documents#
All original documents used, with type (e.g. quarterly, half-year, annual report), publication date and a direct link to the filing (EDINET/SEC/IR). Every superscript number in the report points to an entry in this list; so every figure can be traced back to its place in the original.
| # | Document type | Published | Link |
|---|---|---|---|
| #1 / #101 | 8-K-EX99.1 | 2023-02-03 | Open |
| #2 | 10-K | 2023-02-23 | Open |
| #3 | 10-Q | 2023-05-05 | Open |
| #4 | 8-K-EX99.1 | 2023-05-05 | Open |
| #5 | 10-Q | 2023-08-03 | Open |
| #6 | 8-K-EX99.1 | 2023-08-03 | Open |
| #7 | 10-Q | 2023-11-02 | Open |
| #8 | 8-K-EX99.1 | 2023-11-02 | Open |
| #9 | 8-K-EX99.1 | 2024-02-02 | Open |
| #10 | 10-K | 2024-02-29 | Open |
| #11 | 10-Q | 2024-05-02 | Open |
| #12 / #112 | 8-K-EX99.1 | 2024-05-02 | Open |
| #13 | 10-Q | 2024-08-01 | Open |
| #14 | 8-K-EX99.1 | 2024-08-01 | Open |
| #15 | 10-Q | 2024-10-31 | Open |
| #16 | 8-K-EX99.1 | 2024-10-31 | Open |
| #17 | 8-K-EX99.1 | 2025-01-30 | Open |
| #18 | 10-K | 2025-02-27 | Open |
| #19 | 10-Q | 2025-05-02 | Open |
| #20 | 8-K-EX99.1 | 2025-05-02 | Open |
| #21 | 10-Q | 2025-07-31 | Open |
| #22 | 8-K-EX99.1 | 2025-07-31 | Open |
| #23 | 10-Q | 2025-10-30 | Open |
| #24 | 8-K-EX99.1 | 2025-10-30 | Open |
| #25 / #125 | 8-K-EX99.1 | 2026-02-05 | Open |
| #26 | 10-K | 2026-02-26 | Open |
| #27 | 10-Q | 2026-04-30 | Open |
| #28 / #128 | 8-K-EX99.1 | 2026-04-30 | Open |
| #29 | 10-Q | 2026-07-30 | Open |
| #30 / #130 | 8-K-EX99.1 | 2026-07-30 | Open |
Older sources (+15)
| # | Document type | Published | Link |
|---|---|---|---|
| #201 | 10-K | 2019-02-28 | Open |
| #203 | 10-Q | 2019-02-28 | Open |
| #204 | 10-K | 2019-02-28 | Open |
| #208 | 10-K | 2019-02-28 | Open |
| #205 | 10-Q | 2019-05-02 | Open |
| #202 | 10-Q | 2019-08-01 | Open |
| #206 | 10-Q | 2019-08-01 | Open |
| #207 | 10-Q | 2019-10-31 | Open |
| #212 | 10-K | 2020-02-27 | Open |
| #209 | 10-Q | 2020-05-07 | Open |
| #210 | 10-Q | 2020-08-06 | Open |
| #211 | 10-Q | 2020-11-05 | Open |
| #213 | 10-Q | 2021-05-07 | Open |
| #214 | 10-Q | 2021-08-05 | Open |
| #215 | 10-Q | 2021-11-04 | Open |
FAQ#
Is there a management forecast (guidance) for FY2026?
Yes. Management has issued targets for FY2026, including EPS (non-GAAP). The guidance tracking chapter shows all targets and checks them against the actuals reported later; neutral, with no estimate of our own.
Does The Cigna Group pay a dividend?
The filings report on the dividend; most recent entry: dividends paid $2.4 billion (FY2024) (as reported, no assessment of our own). Details with source links are in the report chapters.
Where can I find the official investor relations documents of The Cigna Group?
The sources chapter links all 50 original filings used (SEC filings) with type, publication date and a direct link; every figure in the report carries a source number.